Search Result

Results for "

glucokinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Glucokinase (42) Biochemical Assay Reagents (1) Drug Isomer (1) Endogenous Metabolite (7) Glycosidase (1) Insecticide (1) Insulin Receptor (1) Isotope-Labeled Compounds (2) MHC (1) mRNA (1) Parasite (1) Reference Standards (6) Sodium Channel (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (3) Infection (1) Inflammation/Immunology (1) Metabolic Disease (55) Neurological Disease (4)
Oligonucleotides:	Transcription Factors (1) mRNA (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: Glucokinase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W040127

Peonidin 3-O-glucoside chloride 1 Publications Verification	Insulin Receptor	Metabolic Disease
Peonidin 3-O-glucoside chloride is an agonist of the free fatty acid receptor FFAR1 and Glucokinase. Peonidin 3-O-glucoside chloride enhances insulin secretion of pancreatic beta cells and increases glucose uptake by liver cells. Peonidin 3-O-glucoside chloride activates FFAR1, promotes the phosphorylation of related proteins in the insulin secretion pathway, and increases the expression of FFAR1. In liver cells, Peonidin 3-O-glucoside chloride activates GK and regulates proteins associated with carbohydrate metabolism. Peonidin 3-O-glucoside chloride can be used in diabetes research .

HY-109030

Dorzagliatin 3 Publications Verification HMS5552	Glucokinase	Metabolic Disease
Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes .

HY-42680

D-Tagatose D-(-)-Tagatose	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Cancer
D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes .

HY-108328

Nerigliatin PF-04937319	Glucokinase	Neurological Disease Metabolic Disease
Nerigliatin (PF-04937319) is a orally active glucokinase activator (GKA) with EC₅₀ value of 154.4 μM. Nerigliatin maintains glucose-lowering efficacy. Nerigliatin causes peripheral nerve degeneration. Nerigliatin can be used in type 2 diabetes research.

HY-15671

GKA50	Glucokinase	Metabolic Disease
GKA50 is a potent *glucokinase* activator (EC₅₀=33 nM at 5 mM glucose). GKA50 stimulates insulin release from mouse islets of Langerhans. GKA50 is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca ²⁺-dependent modulator of insulin secretion. GKA50 shows significant glucose lowering in high fat fed female rats .

HY-15675

AZD1656	Glucokinase	Metabolic Disease
AZD1656 is a potent, selective and orally active *glucokinase* activator with an EC₅₀ of 60 nM. AZD1656 has the potential for type 2 diabetes research .

HY-112253

D-Fructose 1-phosphate	Endogenous Metabolite	Metabolic Disease
D-Fructose 1-phosphate is a key intermediate metabolite in the fructose metabolic pathway. As a key signaling molecule linking fructose metabolism and glucose metabolic regulation, D-Fructose 1-phosphate acts as an allosteric modulator to counteract the inhibitory effect of the glucokinase-regulatory protein complex, thereby finely regulating the direction of hepatic glucose metabolism at the substrate level .

HY-19843

MK-0941	Glucokinase	Metabolic Disease
MK-0941 is a selective, orally active, and allosteric *glucokinase* activator with EC₅₀s of 240 and 65 nM for recombinant human *glucokinase* in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 activates hexokinase subtype IV. MK-0941 can increase insulin secretion and glucose uptake. MK-0941 can be studied in research for type 2 diabetes .

HY-13529

Globalagliatin 1 Publications Verification LY2608204; SY-004	Glucokinase	Metabolic Disease
Globalagliatin (LY2608204) is an orally active glucokinase (GK) activator with an EC₅₀ of 42 nM. Globalagliatin also stimulates glucose metabolism in rat insulinoma INS1-E cells with an EC₅₀ of 579 nM. Globalagliatin targets both pancreatic β-cells and hepatocytes. Globalagliatin is promising for research of type 2 diabetes .

HY-10595

RO-28-1675 3 Publications Verification	Glucokinase	Metabolic Disease
RO-28-1675 is a potent allosteric glucokinase (GK) activator with an EC₅₀ of 54 nM. RO-28-1675 can be used for the research of type 2 diabetes .

HY-12411

AMG-3969 1 Publications Verification	Glucokinase	Metabolic Disease
AMG-3969 is a potent glucokinase-glucokinase regulatory protein interaction (GK-GKRP) disruptor with an IC₅₀ of 4 nM.

HY-100181

PF-04991532	Glucokinase	Metabolic Disease
PF-04991532 is a potent, hepatoselective *glucokinase* activator with EC₅₀s of 80 and 100 nM in human and rat, respectively.

HY-112253A

D-Fructose 1-phosphate disodium 1 Publications Verification	Endogenous Metabolite	Metabolic Disease
D-Fructose 1-phosphate disodium is a key intermediate metabolite in the fructose metabolic pathway. As a key signaling molecule linking fructose metabolism and glucose metabolic regulation, D-Fructose 1-phosphate disodium acts as an allosteric modulator to counteract the inhibitory effect of the glucokinase-regulatory protein complex, thereby finely regulating the direction of hepatic glucose metabolism at the substrate level .

HY-147254

Cadisegliatin TTP-399	Glucokinase	Metabolic Disease
Cadisegliatin (TTP-399) is a potential, orally active liver-selective glucokinase (GK) activator. Cadisegliatin has antihyperglycaemic activity. Cadisegliatin can be used for the research of type 2 diabetes .

HY-131940

3-O-Methyl-N-acetyl-D-glucosamine 3-O-Methyl-GlcNAc	Insecticide	Metabolic Disease
3-O-Methyl-N-acetyl-D-glucosamine is a potent inhibitor of N-acetylglucosamine kinase. 3-O-Methyl-N-acetyl-D-glucosamine potently inhibits glucose phosphorylation by N-acetylglucosamine kinase whereas glucokinase is not at all affected by this hexosamine .

HY-P2761

*Glucokinase*	Biochemical Assay Reagents	Metabolic Disease
Glucokinase is a glucose-phosphorylating enzyme that has an important role in glucose homeostasis. Glucokinase acts as a glucose sensot of pancreatic β-cells. Glucokinase regulates the conversion of glucose to glucogen as well as gluconeogenesis. Glucokinase in mammals can phosphorylate hexoses like mannose or fructose in addition to glucose. Glucokinase can be studied in research on diabetes .

HY-P11060

MC38 SLP Adpgk Adpgk peptide	MHC	Cancer
MC38 SLP Adpgk (Adpgk peptide) is an H-2 K ^b-restricted colorectal cancer neoantigen peptide. MC38 SLP Adpgk is formulated into PCNP nanocomplexes together with CpG ODN. PCNP vaccines significantly enhance the co-delivery efficiency of neoantigens and adjuvants to lymphoid organs, and activate cytotoxic T cells. PCNP vaccines not only protect mice from MC-38 colorectal tumor invasion, but also exhibit anti-tumor efficacy in established colorectal tumor models and significantly prolong the survival of tumor-bearing mice .

HY-100221

AM-2394	Glucokinase	Metabolic Disease
AM-2394 is a structurally distinct *glucokinase* activator (GKA). AM-2394 activates glucokinase (GK) with an EC₅₀ of 60 nM.

HY-144287

Glucokinase activator 3	Glucokinase Sodium Channel	Metabolic Disease
Glucokinase activator 3 is an orally active *Glucokinase* (GK) activator with an AC₅₀ of 38 nM. Glucokinase activator 3 inhibits hERG channel and sodium channel in patch clamp assays. Glucokinase activator 3 exhibits high efficacy in reducing blood glucose in diet-induced obese (DIO) mice. Glucokinase activator 3 has the potential for the research of type 2 diabetes .

HY-133127

AR453588	Glucokinase	Metabolic Disease
AR453588 is a potent and orally bioavailable anti-diabetic *glucokinase* activator, with an EC₅₀ of 42 nM. AR453588 shows anti-hyperglycemic activity .

HY-109030R

Dorzagliatin (Standard) HMS5552 (Standard)	Reference Standards Glucokinase	Metabolic Disease
Dorzagliatin (Standard) is the analytical standard of Dorzagliatin. This product is intended for research and analytical applications. Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes .

HY-U00411

PSN-GK1	Glucokinase	Metabolic Disease
PSN-GK1 is a potent *glucokinase* activator with an EC₅₀ of 0.13 μM.

HY-100181B

(R)-PF-04991532	Drug Isomer	Metabolic Disease
(R)-PF-04991532 is the R-enantiomer of PF-04991532 (HY-100181). PF-04991532 is a potent, hepatoselective glucokinase activator .

HY-14172

NVP-LBX192	Glucokinase	Metabolic Disease
NVP-LBX192 (Compound 17c) is a *glucokinase* activator with a K(a) of 39 nM. NVP-LBX192 can significantly reduce glucose levels. NVP-LBX192 can be used for the research of metabolic disease, such as type 2 diabetes .

HY-144289

BMS-820132	Glucokinase	Metabolic Disease
BMS-820132 is an orally active and partial *glucokinase* (GK) activator with a AC₅₀ of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation .

HY-19494

RO-4597014	Glucokinase	Metabolic Disease
RO-4597014 is a *glucokinase* inhibitor. RO-4597014 can be used in the study of diabetes .

HY-156923

Glucokinase activator 5	Glucokinase	Metabolic Disease
Glucokinase activator 5 (compound 6) is a *glucokinase* activator .

HY-12614

AMG-1694	Glucokinase	Metabolic Disease
AMG-1694 is a potent glucokinase–glucokinase regulatory protein (GK-GKRP) disruptors and promotes the dissociation of the GK-GKRP complex with an IC₅₀ of 7 nM, indirectly increasing GK enzymatic activity. AMG-1694 potently reverses the inhibitory effect of GKRP on GK activity and promotes GK translocation. AMG-1694 normalizes blood glucose levels in several rodent models of diabetes and lowes blood glucose restricted to diabetic and not normoglycaemic animals .

HY-177297

LCZ960 NVP-LCZ960	Glucokinase	Metabolic Disease
LCZ960 is an orally active *glucokinase* (GK) activator. LCZ960 stimulates GK activity in hepatocytes in vitro and stimulates glucose uptake in vivo through hepatic GK activation. LCZ960 lowers blood glucose in mice with diet-induced obesity (DIO). LCZ960 maintains normoglycemia and improves glucose tolerance in DIO mice and rats. LCZ960 stimulates glycogen synthase flux and increases hepatic glycogen turnover in rats. LCZ960 induces increased hepatic glycogen recycling. LCZ960 can be used to study high-fat diet-induced obesity and type 2 diabetes .

HY-169545

Glucokinase activator 8	Glucokinase	Metabolic Disease
Glucokinase activator 8 is an activator for *glucokinase* .

HY-W997026

Glucokinase activator 7	Glucokinase	Metabolic Disease
Glucokinase activator 7 is a *Glucokinase* activator. Glucokinase activator 7 can be used for research of diabetes, hyperglycemia and other diseases (Compound in Page 176 of Ref.) .

HY-101788

Glucokinase activator 1	Glucokinase	Metabolic Disease
Glucokinase activator 1 is a liver-directed *glucokinase* activator with an EC₅₀ of 34 nM.

HY-116946

Glucokinase activator 6	Glucokinase	Metabolic Disease
Glucokinase activator 6 (compound 9) is a potent *glucokinase* activator, with an EC₅₀ of 0.09 μM. Glucokinase activator 6 can be used for type 2 diabetes (T2D) research .

HY-P3257B

*ADP-Specific glucokinase, thermococcus litoralis* ADP-Dependent hexokinase, thermococcus litoralis	Glucokinase	Neurological Disease Metabolic Disease Cancer
ADP-Specific glucokinase, thermococcus litoralis is an ADP-specific glucose kinase expressed in thermophilic archaea. ADP-Specific glucokinase, thermococcus litoralis can catalyze glucose into glucose-6-phosphate, which promotes glycolysis. ADP-Specific glucokinase, thermococcus litoralis can activate T cells and enhance the phagocytic activity of macrophages. ADP-Specific glucokinase, thermococcus litoralis can be used in research on metabolic diseases, neurological disorders, and tumors .

HY-P3257A

*ADP-specific glucokinase, pyrococcus furiosus* ADP-dependent hexokinase, pyrococcus furiosus	Glucokinase	Neurological Disease Metabolic Disease Cancer
ADP-Specific glucokinase, pyrococcus furiosus is an ADP-specific glucose kinase expressed in thermophilic archaea. ADP-Specific glucokinase, pyrococcus furiosus can catalyze glucose into glucose-6-phosphate, which promotes glycolysis. ADP-Specific glucokinase, pyrococcus furiosus can activate T cells and enhance the phagocytic activity of macrophages. ADP-Specific glucokinase, pyrococcus furiosus can be used in research on metabolic diseases, neurological disorders, and tumors .

HY-121070

AZD1092	Glucokinase	Metabolic Disease
AZD1092 is an orally active glucokinase (GK) activator with an EC₅₀ value of 0.03 μM. AZD1092 can be used for the research of Type 2 Diabetes (T2D) .

HY-179419

Glucokinase activator 10	Glucokinase	Metabolic Disease
Glucokinase activator 10, a thiazole-based compound, is a liver-selective and orally active *glucokinase* activator with an EC₅₀ of 42 nM. Glucokinase activator 10 exhibits significant glucose lowering in acute diet-induced obese mouse oral glucose tolerance (OGTT) test. Glucokinase activator 10 can be used for the study of metabolic disorders .

HY-N14596

Glucolipsin A	Glucokinase	Metabolic Disease
Glucolipsin A is a *glucokinase* activator.

HY-N14597

Glucolipsin B	Glucokinase	Metabolic Disease
Glucolipsin B is a *glucokinase* activator.

HY-116682

GKA-71	Glucokinase	Metabolic Disease
GKA-71 is an orally active *Glucokinase* activator, possesses an islet protective effect .

HY-136631

PF-04279405	Glucokinase	Metabolic Disease
PF-04279405 is a potent and full-acting glucokinase (GK) agonist (EC₅₀=23 nM). Glucokinase (GK) is an enzyme responsible for the conversion of glucose to glucose-6-phosphate and plays a key role in maintaining blood glucose homeostasis. PF-04279405 can be used in the research of type 2 diabetes .

HY-19843A

MK-0941 free base	Glucokinase	Metabolic Disease
MK-0941 free base is an orally active *glucokinase* activator, with EC₅₀s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 free base exhibits strong glucose-lowering activity and is a potential therapeutic agent for treatment of type 2 diabetes .

HY-133127A

AR453588 hydrochloride	Glucokinase	Metabolic Disease
AR453588 hydrochloride is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC₅₀ of 42 nM. AR453588 hydrochloride shows anti-hyperglycemic activity .

HY-128663

GLK7-001	Parasite	Infection
GLK7-001 is a Trypanosoma cruzi glucokinase (TcGlcK) inhibitor. GLK7-001 has in vitro trypanocidal activity .

HY-119813

(S,S)-Sinogliatin (S,S)-HMS-5552; (S,S)-RO-5305552	Glucokinase	Metabolic Disease
(S,S)-Sinogliatin ((S,S)-HMS-5552) is the (S,S) -enantiomer of Sinogliatin. Sinogliatin is a *glucokinase* activator that can be used to study type 2 diabetes .

HY-14747

Piragliatin RO4389620	Glucokinase	Metabolic Disease
Piragliatin (RO4389620) is an activator for *glucokinase*, which reduces endogenous glucose production, increases β-cell function and glucose utilization, and thus decreases the blood glucose levels. Piragliatin exhibits antidiabetic efficacy .

HY-156020

Glucocerebrosidase-IN-2	Glycosidase	Metabolic Disease
Glucocerebrosidase-IN-2 (compound 12) is a quinazoline analogue and an inhibitor of glucocerebrosidase (GC). Glucocerebrosidase-IN-2 has the potential to improve GC translocation to lysosomes in Gaucher disease patient-derived cells (mostly carrying the N370S mutation). Glucocerebrosidase-IN-2 inhibits the hydrolysis of 4-methylumbelliferone β-D-glucopyranoside (4MU) and fluorescent glycosylceramide (FlourGC) in N370S mutant tissues with an AC50 of 25.29 μM .

HY-108328R

Nerigliatin (Standard) PF-04937319 (Standard)	Glucokinase Reference Standards	Neurological Disease Metabolic Disease
Nerigliatin (Standard) is the analytical standard of Nerigliatin. This product is intended for research and analytical applications. Nerigliatin (PF-04937319) is a orally active glucokinase activator (GKA) with EC50 value of 154.4 μM. Nerigliatin maintains glucose-lowering efficacy. Nerigliatin causes peripheral nerve degeneration. Nerigliatin can be used in type 2 diabetes research.

HY-174547

Human PDX1 mRNA	mRNA	Metabolic Disease
Human PDX1 mRNA encodes the human pancreatic and duodenal homeobox 1 (PDX1) protein, a transcriptional activator of several genes, including insulin, somatostatin, glucokinase, islet amyloid polypeptide, and glucose transporter type 2. PDX1 may be involved in the early development of the pancreas. It also plays a major role in glucose-dependent regulation of insulin gene expression.

HY-125316

AMG-151 ARRY-403	Endogenous Metabolite	Metabolic Disease
AMG-151 (ARRY-403) is a glucokinase agonist with fasting plasma glucose (FPG) lowering activity. AMG-151 showed a significant linear dose-response trend compared with placebo in a randomized, placebo-controlled Phase IIa study. The use of AMG-151 was associated with a higher incidence of hypoglycemia and hypertriglyceridemia. AMG-151 may serve as a potential compound for the inhibition of type 1 diabetes .

Cat. No.	Product Name

HY-L058

Glycolysis Compound Library

1,258 compounds

Glycolysis is a series of metabolic processes by which one molecule of glucose is catabolized to two molecules of pyruvate with a net gain of two ATP. Glycolysis takes place in 10 steps and catalyzed by a series of enzyme, such as hexokinase, Glucose-6-phosphate isomerase, Phosphofructokinase, etc. Glycolysis is used by all cells in the body for energy generation.

Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply. This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation. Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications.

MCE provides a unique collection of 1,258 glycolysis compounds that mainly target hexokinase, glucokinase, enolase, pyruvate kinase, PDHK, etc. MCE Glycolysis Compound Library is a useful tool for glucose metabolism research and anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P11060

MC38 SLP Adpgk Adpgk peptide	MHC	Cancer
MC38 SLP Adpgk (Adpgk peptide) is an H-2 K ^b-restricted colorectal cancer neoantigen peptide. MC38 SLP Adpgk is formulated into PCNP nanocomplexes together with CpG ODN. PCNP vaccines significantly enhance the co-delivery efficiency of neoantigens and adjuvants to lymphoid organs, and activate cytotoxic T cells. PCNP vaccines not only protect mice from MC-38 colorectal tumor invasion, but also exhibit anti-tumor efficacy in established colorectal tumor models and significantly prolong the survival of tumor-bearing mice .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W040127

Peonidin 3-O-glucoside chloride 1 Publications Verification	Anthocyans Flavonoids Classification of Application Fields Vitis vinifera cv. Zalema Metabolic Disease Plants Vitaceae Disease Research Fields Source Classification	Insulin Receptor
Peonidin 3-O-glucoside chloride is an agonist of the free fatty acid receptor FFAR1 and Glucokinase. Peonidin 3-O-glucoside chloride enhances insulin secretion of pancreatic beta cells and increases glucose uptake by liver cells. Peonidin 3-O-glucoside chloride activates FFAR1, promotes the phosphorylation of related proteins in the insulin secretion pathway, and increases the expression of FFAR1. In liver cells, Peonidin 3-O-glucoside chloride activates GK and regulates proteins associated with carbohydrate metabolism. Peonidin 3-O-glucoside chloride can be used in diabetes research .

HY-42680

D-Tagatose D-(-)-Tagatose	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Sweeteners Saccharides Monosaccharides Source Classification Food Research	Endogenous Metabolite
D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes .

HY-112253

D-Fructose 1-phosphate	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite
D-Fructose 1-phosphate is a key intermediate metabolite in the fructose metabolic pathway. As a key signaling molecule linking fructose metabolism and glucose metabolic regulation, D-Fructose 1-phosphate acts as an allosteric modulator to counteract the inhibitory effect of the glucokinase-regulatory protein complex, thereby finely regulating the direction of hepatic glucose metabolism at the substrate level .

HY-112253A

D-Fructose 1-phosphate disodium 1 Publications Verification	Structural Classification Natural Products Human Gut Microbiota Metabolites Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
D-Fructose 1-phosphate disodium is a key intermediate metabolite in the fructose metabolic pathway. As a key signaling molecule linking fructose metabolism and glucose metabolic regulation, D-Fructose 1-phosphate disodium acts as an allosteric modulator to counteract the inhibitory effect of the glucokinase-regulatory protein complex, thereby finely regulating the direction of hepatic glucose metabolism at the substrate level .

HY-N14596

Glucolipsin A	Microorganisms Macrolide Antibiotics Antibiotics Source Classification	Glucokinase
Glucolipsin A is a *glucokinase* activator.

HY-N14597

Glucolipsin B	Microorganisms Macrolide Antibiotics Antibiotics Source Classification	Glucokinase
Glucolipsin B is a *glucokinase* activator.

HY-42680R

D-Tagatose (Standard) D-(-)-Tagatose (Standard)	Structural Classification Microorganisms Endogenous metabolite Saccharides Monosaccharides Source Classification	Reference Standards Endogenous Metabolite
D-Tagatose (Standard) is the analytical standard of D-Tagatose (HY-42680). This product is intended for research and analytical applications. D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.

Species:	Human (2)
Tag:	His (1) Tag Free (2)
Source:	P. pastoris (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P75790

	Glucokinase/GCK Protein, Human Hexokinase-4; HK4; Hexokinase-D; glucokinase	Human	E. coli
	Glucokinase/GCK proteins catalyze hexose phosphorylation, converting D-glucose, D-fructose, and D-mannose into their respective hexose 6-phosphates. Glucokinase/GCK Protein, Human is the recombinant human-derived Glucokinase/GCK protein, expressed by E. coli , with tag free.

HY-P703524

	*Polyphosphate glucokinase* Protein, Thermobifida fusca** Thermobifida fusca (strain YX); Kinase; Transferase	Others	E. coli
	Polyphosphate glucokinase Protein, Thermobifida fusca is the recombinant Polyphosphate glucokinase protein, expressed by E. coli, with tag free tag.

HY-P71822

	GCKR Protein, Human (P.pastoris, His) FGQTL5; GCK ; GLRE; glucokinase regulatory protein; Hexokinase 4 regulator; Hexokinase-D; HK IV; HK4	Human	P. pastoris
	The GCKR protein plays a critical regulatory role in glucokinase (GCK) by forming an inactive complex and recruiting GCK to the nucleus after meals. Its interaction with GCK is finely tuned by fructose metabolites; binding of GCKR to fructose-6-phosphate increases the affinity for GCK, whereas binding to fructose-1-phosphate decreases the affinity, thereby releasing inhibition. GCKR Protein, Human (P.pastoris, His) is the recombinant human-derived GCKR protein, expressed by P. pastoris , with N-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-42680S1

D-Tagatose-13C-1

D-Tagatose- ¹³C-1 is the ¹³C labeled D-Tagatose (HY-42680). D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.

HY-42680S

D-Tagatose-13C

D-Tagatose- ¹³C is the ¹³C labeled D-Tagatose (HY-42680). D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.

Host:	Mouse (1) Rabbit (1)
Reactivity:	Human (2)
Application:	WB (2) ELISA (1)
Isotype:	IgG (1)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (2) Recombinant (1)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P85184

	Glucokinase Antibody (YA4876) GCK; glucokinase; Hexokinase type IV; HK IV; Hexokinase-4; HK4; Hexokinase-D	WB, ELISA	Human
	Glucokinase Antibody (YA4876) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Glucokinase.

HY-P82295

	Glucokinase Antibody (YA2040) GCK; glucokinase; Hexokinase type IV; HK IV; Hexokinase-4; HK4; Hexokinase-D	WB	Human
	Glucokinase Antibody (YA2040) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Glucokinase.